Finding new scaffolds of JAK3 inhibitors in public database: 3D-QSAR models & shape-based screening
详细信息 查看全文
- 作者：Changdev G. Gadhe ; Eunhee Lee ; Mi-hyun Kim
- 关键词：Diversity of scaffolds ; 3D ; QSAR ; Shape ; based screening ; Anti ; inflammatory ; JAK3 inhibitors
- 刊名：Archives of Pharmacal Research
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：38
- 期：11
- 页码：2008-2019
- 全文大小：1,711 KB
- 参考文献：Ashburn, T.T., and K.B. Thor. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 3: 673–683.CrossRef PubMed
Bickerton, G.R., G.V. Paolini, J. Besnard, S. Muresan, and A.L. Hopkins. 2012. Quantifying the chemical beauty of drugs. Nature Chemistry. 4: 90–98.PubMedCentral CrossRef PubMed
Feng, B.Y., A. Shelat, T.N. Doman, R.K. Guy, and B.K. Shoichet. 2005. High-throughput assays for promiscuous inhibitors. Nature Chemical Biology 1: 146–148.CrossRef PubMed
Glide v6.2. 2014. Schrödinger. New York: LLC.
Hughes, J.P., S. Rees, S.B. Kalindjian, and K.L. Philpott. 2011. Principles of early drug discovery. British Journal of Pharmacology 162: 1239.PubMedCentral CrossRef PubMed
Hawkins, P.C., A.G. Skillman, G.L. Warren, B.A. Ellingson, and M.T. Stahl. 2010. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. Journal of Chemical Information and Modeling 50: 572–584.PubMedCentral CrossRef PubMed
Hawkins, P.C., and A. Nicholls. 2012. Conformer generation with OMEGA: Learning from the data set and the analysis of failures. Journal of Chemical Information and Modeling 52: 2919–2936.CrossRef PubMed
Huang, N., B.K. Shoichet, and J.J. Irwin. 2006. Benchmarking sets for molecular docking. Journal of Medicinal Chemistry 49: 6789–6801.PubMedCentral CrossRef PubMed
Horvath, D., G. Marcou, and A. Varnek. 2013. Do not hesitate to use Tversky-and other hints for successful active analogue searches with feature count descriptors. Journal of Chemical Information and Modeling 53: 1543–1562.CrossRef PubMed
Ivashkiv, L.B., and X. Hu. 2003. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis and Rheumatism 48: 2092–2096.CrossRef PubMed
Jaime-Figueroa, S., J. De Vicente, J. Hermann, A. Jahangir, S. Jin, A. Kuglstatter, et al. 2013. Discovery of a series of novel 5H-pyrrolo [2, 3-b] pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 23: 2522–2526.CrossRef
Koncz, T., M. Pentek, V. Brodszky, K. Ersek, E. Orlewska, and L. Gulacsi. 2010. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opinion on Biological Therapy 10: 1367–1378.CrossRef PubMed
Krzywinski, M., and N. Altman. 2014. Points of significance: Visualizing samples with box plots. Nature Methods 11: 119–120.CrossRef PubMed
Kubinyi, H., G. Folkers, and Y.C. Martin. 1998. 3D QSAR in drug design. In Three-dimensional quantitative structure activity relationships, ed. H.D. Hoeltje, and W. Sippl. Dordrecht: Kluwer Academic Publishers.
Lynch, S.M., J. DeVicente, J.C. Hermann, S. Jaime-Figueroa, S. Jin, A. Kuglstatter, et al. 2013. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome. Bioorganic and Medicinal Chemistry Letters 23: 2793–2800.CrossRef PubMed
Macarron, R., M.N. Banks, D. Bojanic, D.J. Burns, D.A. Cirovic, T. Garyantes, et al. 2011. Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery 10: 188–195.CrossRef PubMed
MacroModel. 2014. v., Schrödinger. New York: LLC.
Maestro v9.6. 2014. Schrödinger. New York: LLC.
Nicholls, A. 2014. Confidence limits, error bars and method comparison in molecular modeling. Part 1: The calculation of confidence intervals. Journal of Computer-Aided Molecular Design 28(9): 887–918.PubMedCentral CrossRef PubMed
OMEGA. 2014. v. OpenEye Scientific Software. Santa Fe: OMEGA.
ROCS. v. OpenEye Scientific Software. Santa Fe: ROCS.
Roy, A., P.R. McDonald, S. Sittampalam, and R. Chaguturu. 2010. Open access high throughput drug discovery in the public domain: A Mount Everest in the making. Current Pharmaceutical Biotechnology 11: 764.PubMedCentral CrossRef PubMed
Russell, S.M., N. Tayebi, H. Nakajima, M.C. Riedy, J.L. Roberts, M.J. Aman, et al. 1995. Mutation of Jak3 in a patient with SCID: Essential role of JAK3 in lymphoid development. Science 270: 797–800.CrossRef PubMed
Shuai, K., and B. Liu. 2003. Regulation of JAK–STAT signalling in the immune system. Nature Reviews Immunology 3: 900–911.CrossRef PubMed
SYBYL-X2.1. Tripos International. St. Louis: SYBYL-X2.1.
Tropsha, A. 2010. Best practices for QSAR model development, validation, and exploitation. Molecular Informatics 29: 476–488.CrossRef - 作者单位：Changdev G. Gadhe (1) (2)
Eunhee Lee (1) (2)
Mi-hyun Kim (1) (2)
1. Department of Pharmacy, College of Pharmacy, Gachon University, 155 Gaetbeol-ro, Yeonsu-gu, Incheon, Republic of Korea
2. Gachon Institute of Pharmaceutical Science, Gachon University, Yeonsu-gu, Incheon, Republic of Korea - 刊物主题：Pharmacy; Pharmacology/Toxicology;
- 出版者：Springer Netherlands
- ISSN：1976-3786
文摘